MRPS26

Across TCGA pan-cancer cohorts, MRPS26 RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of MRPS26’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MRPS26 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MRPS26 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

BLCA, COAD, and STAD are the cancer types where MRPS26 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MRPS26 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Female	III,IV	+1.082	<.001	12	view →
COAD	Female	All	+1.410	<.001	11	view →
STAD	All	II,III,IV	+1.024	<.001	9	view →
LUSC	Female	All	+1.139	<.001	8	view →
LIHC	Female	II,III,IV	+0.880	<.001	8	view →
HNSC	Male	III,IV	+0.871	<.001	8	view →
BRCA	All	III,IV	+0.759	<.001	6	view →
UCEC	All	All	+0.717	<.001	6	view →
CHOL	Male	All	+1.426	<.001	5	view →
READ	All	II,III,IV	+0.887	.017	4	view →
THCA	Male	III,IV	−0.617	.003	4	view →
KIRP	All	II,III,IV	+0.443	.012	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

MRPS26–BLCA

Open the BLCA breakdown →